Moleculin Biotech, Inc. (MBRX) vs Nuwellis, Inc. (NUWE)

A side-by-side comparison of Moleculin Biotech, Inc. and Nuwellis, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Moleculin Biotech, Inc. logo
MBRX
Moleculin Biotech, Inc.
$2M
$0.46HealthcareDelayed quote: Oct 6, 2026, 11:46 AM EDT
Nuwellis, Inc. logo
NUWE
Nuwellis, Inc.
$3M
$0.72HealthcareDelayed quote: Oct 6, 2026, 11:47 AM EDT

Total return — MBRX vs NUWE

growth of $100 · dividends reinvested · last 7y
MBRX -99.1% (-49.0%/yr)NUWE -100.0% (-89.2%/yr)MBRX compounded faster over this window
Log scale — wide-divergence pair
000001101001kStart $100201820202022$1$0
MBRX NUWE

MBRX vs NUWE: by the numbers

  • •NUWE is the larger company ($3M vs $2M market cap).
  • •Both run net losses; MBRX's is the smaller (0.00% vs -123.38% net margin).

Metrics side by side

Valuation

MetricMBRXNUWE
P/S ratioN/A0.29
P/B ratio0.21N/A

Profitability

MetricMBRXNUWE
Gross margin0.00%69.69%
Operating margin0.00%-140.62%
Net margin0.00%-123.38%
ROE-261.73%N/A
ROIC-242.25%-238.32%

Growth (annualized)

MetricMBRXNUWE
Revenue CAGR (5Y)N/A1.48%
Total return CAGR (5Y)-78.48%N/A

Go deeper

Full MBRX analysisFull NUWE analysisInteractive comparison tool

Dig into the metrics

Moleculin Biotech ROENuwellis ROEMoleculin Biotech operating marginNuwellis operating marginMoleculin Biotech revenue growthNuwellis revenue growthMoleculin Biotech free cash flowNuwellis free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.